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Abstract: Cell-based functional assays used for compound screening and lead optimization play an important role in drug 
discovery for G-protein coupled receptors (GPCRs). Cell-based assays can define the role of a compound as an agonist, 
antagonist or inverse agonist and can provide detailed information about the potency and efficacy of a compound. In addi-
tion, cell-based screens can be used to identify allosteric modulators that interact with sites other than the binding site of 
the endogenous ligand. Intracellular calcium assays which use a fluorescent calcium binding dye (such as Fluo-3, Fluo-4 
or Fura-2) have been used in compound screening campaigns to measure the activity of Gq-coupled GPCRs. However, 
such screening methodologies require a special instrumentation to record the rapid change in intracellular free calcium 
concentration over time. The radioactive inositol 1,4,5- triphosphate (IP3) assay measures 
3H-inositol incorporation and is 
another traditional assay for the assessment of Gq-coupled GPCR activity, but it is not suitable for screening of large size 
compound collections because it requires a cell wash step and generates radioactive waste. To avoid these limitations, we 
have optimized and miniaturized a TR-FRET based IP-One assay that measures inositol monophosphate in a 1536-well 
plate format. This assay is homogenous, non-radioactive and does not require a kinetic readout. It has been tested with the 
cell lines expressing M1 acetylcholine, FFAR1, vasopressin V1b, or Neuropeptide S receptors. The activities of antago-
nists determined in the IP-One assay correlated well with these measured in the intracellular calcium assay while the cor-
relation of agonist activities might vary from cell line to cell line. This IP-One assay offers an alternative method for high 
throughput screening of Gq-coupled GPCRs without using costly kinetic plate readers. 
INTRODUCTION  
  Guanine nucleotide triphosphate binding protein (G pro-
tein)-coupled receptors (GPCRs) are the largest and most 
important family of cell surface receptors for drug develop-
ment. It is estimated that over 30% of all marketed small-
molecule drugs target GPCRs [1]. When binding to appro-
priate ligands, GPCRs transduce these extracellular stimuli 
into intracellular second messengers through activation of 
one or several G proteins including the subtypes of Gs, Gi, 
and Gq. The Gs subtype activates adenylyl cyclase (AC), 
and thus increases the intracellular adenosine 3’,5’-cyclic 
monophosphate (cAMP), a secondary messenger that signals 
through the activation of protein kinase A (PKA). The Gi 
subtype inhibits AC and suppresses the signaling in the 
cAMP/PKA pathway. The Gq subtype activates phosholi-
pase C (PLC), which increases the second messengers inosi-
tol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG), re-
sulting in an increase of intracellular free Ca
2+ and activation 
of protein kinase C (PKC) [2].  
  A variety of methods have been used to screen for com-
pounds that modulate GPCR signaling. These include meas-
uring direct ligand-receptor binding, level of second messen-  
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gers, receptor internalization, or expression of reporter genes 
[3,4]. Ligand binding assays are used to determine the bind-
ing affinity of compounds to a particular GPCR, either di-
rectly (saturation binding) or indirectly (displacement bind-
ing). However, this type of assay can not differentiate the 
function of compounds and is limited by the availability of 
labeled ligand. Moreover, compounds that bind to a different 
site on the receptor may not affect the binding of labeled 
ligand in this type of assay. Reporter gene assays couple 
GPCR signaling transduction pathway to the expression 
level of an exogenous enzyme such as luciferase or beta-
lactamase. This type of assay is usually very sensitive to 
stimulation by an agonist and can be used as a functional 
assay for compound screening. However, the false positive 
rate in reporter gene assays is often much higher than other 
types of assays, which is resulted from the compound’s ac-
tions on other proteins in the signaling pathway as well as on 
the receptor protein’s transcription and synthesis. Second 
messenger assays are usually cell-based and can be used to 
screen for agonists, antagonists and inverse agonists. Be-
cause second messengers are closer to the initial GPCR sig-
naling events, second messenger assays directly reflect the 
effect of a compound and thus are more trustworthy than the 
reporter gene assay. Several types of cAMP assays are cur-
rently available for screening of compound libraries against 
the Gs/Gi-coupled receptors [3,4], including fluorescence 
polarization (FP) [5] , time-resolved fluorescence resonance 
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time resolved fluorescence) [6] and Lance, AlphaScreen [7], 
enzyme fragmentation complementation (EFC) 8 and cyclic 
nucleotide gated ion channel (CNG)-coupled [9] assays. 
  The radioactive IP3 assay has been used to measure the 
function of Gq coupled GPCRs for many years since the 
discovery of IP3 as a second messenger [10], but the screen-
ing throughput of an IP3 assay, based on 
3H-inositol incorpo-
ration and ion exchange chromatography, is very small and 
is not suitable for HTS. Despite the recent improvement of 
the IP3 assay throughput with the scintillation proximity as-
say (SPA) technology, it still requires a cell wash step and is 
not practical for compound screening with large compound 
libraries [11,12]. Alternatively, the function of Gq-coupled 
GPCRs can be determined by the measurement of intracellu-
lar calcium concentration [12,13]. In the last 10 years, the 
intracellular calcium assays, based on fluorescence dyes in-
cluding Fluo-3, Fluo-4 or Fura-2 that become fluorescent 
upon their binding to free Ca
2+, have been developed and 
applied for compound screening; along with the available 
instruments including Fluorescent-Imaging Plate Reader 
(FLIPR) and Functional Drug Screening System (FDSS). 
But use of this assay format has been limited by the need for 
these special and costly florescence kinetic plate readers. 
Recently, an IP-One assay which utilizes the HTRF detec-
tion format has emerged as an alternative method for the 
functional measurement of Gq-coupled GPCRs [14]. This 
assay applies a specific antibody to quantify the amount of 
inositol-1-phosphate (IP1) accumulation in cells and it is sen-
sitive since HTRF is used as the detection method. We report 
here the miniaturization and optimization of this IP-One as-
say with four GPCRs as well as a comparison of antagonist 
screens against M1 muscarinic acetylcholine receptor ex-
pressed in Chinese hamster ovary (CHO) cells using both the 
IP-One assay and the intracellular calcium assay. 
MATERIALS AND METHODS  
Materials 
  All cell culture reagents were obtained from Invitrogen 
(Carlsbad, CA). Carbachol, pirenzepine, atropine and pro-
benecid were purchased from Sigma Aldrich (St. Louis, 
MO). The 1536-well tissue culture-treated, clear-bottom 
black plates and solid white plates were purchased from Ka-
lypsys (San Diego, CA). The IP-One HTRF assay kit was 
obtained from Cisbio (Bedford, MA). The Fluo-4 containing 
no-wash PBX calcium assay kit was purchased from BD 
Biosciences (Rockville, MD). A CHO cell line expressing 
the murine M1 muscarinic acetylcholine receptor (CHO-M1) 
was obtained from American Type Culture Collection 
(ATCC, Manassas, VA) 
Compound Library 
  A compound library containing 1208 compounds (Li-
brary of Pharmacologically Active Compounds, LOPAC) 
was purchased from Sigma-Aldrich and dissolved in DMSO 
to a concentration of 10 mM. All compounds in the LOPAC 
Library were serially diluted in DMSO to fifteen concentra-
tions in 384-well plates at a ratio of the square root of 5 
(1:2.236) as described previously [15]. Four sets of the inter-
plate dilution plates were subsequently reformatted into one 
set of 1536-well plates at 7 μl/well with concentrations rang-
ing from 0.29 μM to 10 mM as the compound source plates.  
Cell Culture and Frozen Cell Preparation 
 CHO-M1 cells were maintained in F12 Kaighn’s media 
supplemented with 10 % FBS, 100 units/ml penicillin, 100 
μg/ml streptomycin and 250 μg/ml geneticin at 37 ºC, 5 % 
CO2 in a humidified atmosphere. For the frozen cell prepara-
tion, 5  10
6 cells in 60 ml of media were seeded in each 
Nunclon triple layer flask (Nalge Nunc International, Roch-
ester, NY) and were cultured for 3 to 4 days to reach 90-95 
% confluence. The cells were then detached by incubation 
with 15 ml 0.12 % trypsin at 37 °C for 3 minutes and centri-
fuged at 1000 RPM to remove the trypsin solution. The re-
sulting cell pellet was resuspended in the cell freezing media 
containing 10 % DMSO (Invitrogen) at a density of 4  10
7 
cells/ml. One triple layer flask (500 cm
2) yielded approxi-
mately 4 to 5  10
7 cells. Aliquots of cells with 0.5 – 1 ml 
per vial were put in a Cryo 1°C freezing container (Nalgene 
Nunc, Rochster, NY) and slowly frozen down overnight in a 
-80°C freezer at 1°C/min. The frozen cells were then trans-
ferred to liquid nitrogen for storage for up to two years.  
Instruments for Liquid Handling and Plate Detection 
  Cells and other reagents were dispensed into 1536-well 
plates by either a flying reagent dispenser (FRD) (Aurora 
Discovery, San Diego, CA) or a Multidrop Combi dispenser 
(Thermo Fisher Scientific Inc., Waltham, MA). The control 
compounds were serially diluted in DMSO in 384-well 
plates manually and then reformatted into 1536-well plates at 
7  μl/well using Cybi-well dispensing station (Cybio, Inc., 
Woburn, MA). A pintool station (Kalypsys, San Diego, CA) 
was used to transfer 23 nl of compound in DMSO solution to 
the 1536-well assay plate in which the final DMSO concen-
tration was under 0.5%. A CCD-based imaging plate reader, 
ViewLux (PerkinElmer, Boston, MA), was used for the de-
tection of IP-One assay plates in the TR-FRET mode with 
the excitation of 320 nm and the dual emissions of 620 and 
665 nm. A kinetic fluorescence plate reader, Functional Drug 
Screening System (FDSS) 7000 (Hamamatsu Corp., Ha-
mamatsu City, Japan), was used to measure changes in the 
intracellular free calcium.  
HTRF IP-One Assay 
 Frozen  CHO-M1 Cells were resuspended in the culture 
media and seeded at 4 μl/well (2000 cells/well) in white, 
solid bottom, tissue culture-treated 1536-well plates. The 
cells were cultured at 37 ºC, 5 % CO2 overnight to allow 
recovery from the frozen state. Serial dilutions of com-
pounds were then added at 23 nl/well on the second day and 
incubated for 10 min. The agonist carbachol was prepared in 
the stimulation buffer (10mM Hepes, 1mM CaCl2, 0.5 mM 
MgCl2, 4.2 mM KCl, 146 mM NaCl, 5.5 mM glucose 
250mM LiCl 50mM pH7.4) and was added to the assay plate 
at 1 μl/well. After 30 min incubation with carbachol at 37 ºC 
with 5 % CO2, all wells in the assay plate were dispensed 
with 1 μl/well of d2-conjugated IP1 (d2-IP1) and 1 μl/well of 
Eu
+ cryptate-conjugated anti-IP1 antibody (Eu
+-Ab), both 
from the HTRF IP-One kit and prepared in the cell lysis 
buffer supplied in the kit. After 10 min incubation at room 
temperature, the assay plates were measured in the TR-FRET 
detection mode with a ViewLux plate reader. The results 
were calculated as a ratio of the acceptor fluorescence inten-
sity divided by the donor fluorescence intensity [16].  72    Current Chemical Genomics, 2008, Volume 1  Liu et al. 
Intracellular Calcium Assay 
  The resuspended frozen cells were plated at 3 μl/well 
with 2000 cells in black, tissue culture treated, clear bottom 
1536-well plates. After overnight incubation at 37 ºC, 5% 
CO2, 2.5 μl of the calcium dye (1x calcium indicator in 
HBSS with 2.5 mM Probenecid as per manufacturer’s in-
structions) was dispensed to all wells and plates were incu-
bated at 37 ºC, 5 % CO2 for 1 hour followed by 10 min incu-
bation with 23 nl compound in DMSO solution. The assay 
plates were then placed in the kinetic fluorescence plate 
reader (FDSS-7000) for a kinetic measurement of changes in 
intracellular free calcium. The basal fluorescence signal was 
recorded 6 times at 1 Hz followed by an addition of 1 μl of 
Carbachol and 4-minute continuously recording at 1 Hz.  
Data Analysis 
  The primary screening data was first analyzed using 
software developed internally in NIH Chemical Genomics 
Center for the curve fitting and curve classification that is 
available for open access (www.ncgc.nih.gov) [15]. The re-
sults from experiments with control compounds were ana-
lyzed with Prism
® software (GraphPad, San Diego, CA) for 
the curve fitting and EC50/IC50 calculation.  
RESULTS AND DISCUSSION 
  Agonist binding to a Gq-coupled GPCR results in activa-
tion of PLC, which hydrolyzes phosphatidylinositol bisphos-
phate (PIP2) to form two second messengers, IP3 and DAG 
(Fig. 1). While DAG activates protein kinase C (PKC), IP3 
activates the IP3 receptor on the endoplasmic reticulum (ER) 
that results in an efflux of Ca
2+ from ER to cytoplasm and 
elevation of intracellular free Ca
2+. These events transfer the 
extracellular signal to biological responses in cells [10]. The 
IP3 is very rapidly hydrolyzed to IP2, then to IP1 and finally 
to inositol by a series of enzymes; meanwhile Ca
2+ is quickly 
pumped back into ER by a calcium pump on the ER mem-
brane. Both processes effectively switch off the IP3 and Ca
2+ 
signaling. The time frames for intracellular free Ca
2+ and IP3 
measurements are usually within a few seconds to a few 
minutes [3,17]. For compound screens, the changes in intra-
cellular free Ca
2+ concentration can be measured by fluores-
cence calcium dyes with a fluorescence kinetic plate reader 
(Fig. 1a). As an alternative method for assessing the function 
of Gq-coupled GPCRs, IP3 or total IPs including IP1, IP2 and 
IP3 are usually measured in the presence of lithium, an in-
hibitor of inositol monophosphatase (Fig. 1b). In this newly 
available HTRF based IP-One assay, an IP1 specific antibody 
is used to detect the labeled IP1 tracer. When the IP1 level in 
the cell lysate elevates that is proportional to an increase in 
IP3, the TR-FRET between the labeled antibody and IP1 
tracer is disrupted (Fig. 1b).  
IP-One Assay in the 1536-Well Plate Format 
  The original IP-One assay was developed in 96/384-well 
plate formats and requires a medium change for adherent 
cells or use of freshly detached suspension cells [14,18]. The 
additional cell wash step is obviously not suitable for HTS 
especially in 1536-well plate format. The automated robotic 
operation in HTS requires continuous supply of live cells 
over many hours. Adherent cells cultured overnight in assay 
plates are usually the convenient source of live cells for this 
purpose. Alternatively, for screenings using the compound 
pre-dispensed assay plates, suspension cells are needed in 
which the cells can be washed in batch before dispensing 
into the assay plates. Thus, we had miniaturized the IP-One 
assay in both adherent and suspension cell modes in 1536-
well plates. 
Plate Wash vs. no Plate Wash 
  Medium removing or cell wash was suggested previously 
for the IP-One assay in order to reduce to potential interfer-
ence from serum and phosphates present in the cell culture 
medium, reducing the liquid volume in wells, and maintain-
ing the final lithium concentration [14,18]. We performed an 
assay with a cell wash step (cell culture medium was 
changed to buffer) to compare with that without a cell wash 
using adherent cells cultured overnight in 1536-well plates. 
LiCl, an inositol monophosphatase inhibitor, was added at a 
final concentration of 50 mM to accumulate inositol phos-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of the principles for the intracellular calcium assay and the IP-One assay.  
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phates including IP1. We found that eliminating cell wash 
step did not reduce the fluorescence intensities of either do-
nor or acceptor fluorophores or change the acceptor/donor 
fluorescence ratio (Fig. 2). In fact, the signal-to-basal (S/B) 
ratio was slightly higher in the assay without a cell wash 
compared with that with a cell wash. This indicates that the 
cell wash step in 1536-well plates with small assay volume is 
not necessary for this IP-One assay. The IP-One assay in 
homogenous assay format is more suitable for HTS. The 
small amount (4 μl/well) of cell culture media in 1536-well 
plates might reduce the negative effect of phosphate contain-
ing medium on the IP-One assay.  
Adherent Cells vs. Suspension Cells 
  In the adherent cell mode of the IP-One assay, resus-
pended frozen cells were used for cell plating in 1536-well 
assay plates instead of freshly cultured cells because frozen 
cells were readily available and convenient for HTS [19]. 
We found that the S/B ratios in the adherent cell mode with 
1000, 2000, 3000, 4000 cells/well were 1.84, 2.40, 3.01 and 
3.39 fold, respectively. The EC50 values of Carbachol re-
mained the same in these cell densities (Fig. 3a). In the sus-
pension cell mode of IP-One assay, freshly detached cultured 
cells were resuspended in a phosphates-free buffer included 
in the IP-One assay kit. The IP-One assay was then per-
formed immediately after the cells were dispensed to 1536-
well assay plates. We found that 2000 and 4000 cells/well in 
the suspension cell mode did not produce the same levels of 
signal as these in the adherent cell mode (Fig. 3b). A 3.56 
fold of S/B ratio was obtained in the suspension assay mode 
only after the cell density increased to 10,000 cells/well as it 
was reported previously in 384-well plates [14,18]. The re-
sults indicate that a higher cell density in the suspension cell 
mode is needed and the adherent cell mode requires much 
less cells. Frozen cells were tested in the suspension cell 
mode and they did not produce enough signals, while use of 
cell culture medium with 10% FBS produced similar signal 
as the phosphate-free buffer in the suspension cell mode 
(data not shown). Two reasons are likely to account for the 
difference of cell numbers in these two assay modes. First, 
cell numbers increase or even double after overnight culture 
in the adherent cell mode. Second, the cell health condition 
in assay plates can also affect the assay signal. The process 
for preparing freshly suspended cells involves cell detach-
ment, centrifugation, resuspension and plating that can cause 
the stress and/or injury to cells. Thus, more cell numbers are 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Comparison between the “wash” and “no wash” protocols for the IP-One assay. (a) The fluorescence intensity of the fluorescence 
donor and acceptor when assayed with the “wash” or “no wash” protocol. (b) HTRF ratios determined with the “wash” or “no wash” proto-
col. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Comparison between the adherent cell mode and the suspension cell mode for the IP-One assay. (a) Carbachol dose-response curves 
for the IP-One assay were determined with different densities of adherent cells. (b) Carbachol dose-response curves for the IP-One assay 
were determined with different densities of suspension cells. 74    Current Chemical Genomics, 2008, Volume 1  Liu et al. 
needed to produce the same amount of IP1 in the suspension 
cell mode because the freshly plated cells are not fully re-
covered from the stress/injury, whereas the cells in the ad-
herent cell mode are recovered after overnight cell culture 
and have better responses in the experiment. We selected 
2000 cells/well for the compound screen in the adherent cell 
mode for the rest of study considering the cells reached 80 to 
90 % confluence after overnight incubation. A density of 
8000 to 10,000 cells/well in 1536-well plates is recom-
mended for the IP-One assay in the suspension cell mode. 
  The results also indicated that the EC50 values of car-
bachol obtained from both adherent and suspension cells 
were similar (Fig. 3). This result was consistent with previ-
ous reports that the responses of frozen cells after overnight 
culture were comparable to the freshly detached cells in sev-
eral other assays [19,20].  
  The effect of FBS concentration on the assay perform-
ance was also tested in the M1-CHO cells. We found that 
although the EC50 value of Carbachol was not changed in the 
1% FBS medium compared to that in the 10 % FBS medium 
(Fig. 4a), the S/B ratio decreased from 2.21 fold in 10 % 
FBS to 1.87 fold in 1 % FBS medium. This can be explained 
by the decreased amount of IP1 produced in 1% FBS cul-
tured cells compared with the 10% FBS cultured cells. With 
a consideration of better S/B ratio for the antagonist screen-
ing, 10 % FBS medium was selected for this IP-One as-
say. We also found that the DMSO concentration was toler-
ated up to 1 % in this IP-One assay (Fig. 4b). If the use of 
10% FBS concentration is a concern, either 1% FBS medium 
or the suspension cell mode with a higher cell density can be 
used. 
Comparison of Agonist Responses Between the IP-One 
and Intracellular Calcium Assays 
  Carbachol concentration responses in the same M1-CHO 
cells were determined in both the IP-One assay and intracel-
lular calcium assay with a fluorescent calcium dye using a 
fluorescence kinetic plate reader. We found that EC50 value 
of carbachol was 535 nM determined in the IP-One assay 
(Fig. 5a), similar to that reported previously obtained in the 
radioactive IP1 assay with 
3H-inositol incorporation [11,14]. 
The EC50 value of carbachol determined from the intracellu-
lar calcium assay in the fluorescence kinetic measurement 
was 15.1 nM that is similar to that of 23 nM reported else-
where (www.invitrogen.com/) but was 35 fold more potent 
than that determined from the IP-One assay (Fig. 5a). This 
discrepancy of carbachol potency can be explained by the 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Effects of serum and DMSO on the performance of the IP-One assay. (a) Effect of FBS concentration on the assay performance. (b) 
Effect of DMSO concentration on the assay performance. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Comparison of agonist and antagonist activities determined in IP-One and intracellular calcium assays. (a) Concentration responses 
of carbachol. (b) Concentration-responses of muscarinic acetylcholine antagonists. The EC80 amount of agonist, carbachol, was used in both 
assays (5 μM for the IP-One assay and 0.1 μM for the intracellular calcium assay). Comparison on Functional Assays for Gq-Coupled GPCRs  Current Chemical Genomics, 2008, Volume 1    75 
receptor reserve (spare receptor) theory. The carbachol dis-
sociation constant for the receptor binding was reported pre-
viously to be 1-3 μM [21,22] while its EC50 for the intracel-
lular calcium assay was 15.1 to 23 nM. This suggested that 
only a small portion of receptors in this M1-CHO cell line 
need to be activated to stimulate a full calcium response. 
This discrepancy of the carbachol potency might be partly 
due to the different agonist incubation time in two assays. 
The agonist response in the intracellular calcium assay was 
measured at 1-2 minutes as it reaches its peak whereas the 
agonist incubation time in the IP-One assay was 30 minutes 
in order to reach its peak response. In addition, other un-
known factors related to a specific receptor may be responsi-
ble for this discrepancy.  
  The agonist responses of three other Gq-coupled GPCR 
cell lines including the free fatty acid receptor 1 (FFAR1), 
the vasopressin V1b receptor and the neuropeptide S (NPS) 
receptor were also determined in both IP-One and intracellu-
lar calcium assays. We found that the EC50 values of agonists 
determined in the intracellular calcium assay for FFAR1 
receptor and NPS receptor were similar to these determined 
from IP-One assay (Table 1). The EC50 values of NPS in the 
intracellular calcium assay and IP-One assay were 0.22 and 
0.41 nM, respectively. The Kd value of NPS receptor bind-
ing was 0.33 nM reported previously [23], correlating well 
with the activities determined from both functional assays. 
However, the agonist activity to V1b receptor was 34.4 times 
more potent than that obtained in the IP-One assay (Table 1). 
The extent of left shift of the agonist responses in the intra-
cellular calcium assay with the V1b receptors was similar to 
that observed in the M1-CHO cell line.  
Comparison of Antagonist Responses Between the IP-
One and Intracellular Calcium Assays 
  Two muscarinic acetylcholine receptor antagonists, atro-
pine and pirenzepine were tested in both assays to compare 
their activities. Atropine is a nonselective muscarinic acetyl-
choline receptor antagonist and pirenzepine is a M1 selective 
antagonist. In the experiments with antagonist screening, an 
EC80 amount of carbachol (agonist) was added to stimulate 
the M1 receptor responses. Because of the difference of ago-
nist potency in these two assays, 0.1 and 5 μM Carbachol 
were used in the intracellular calcium assay and IP-One as-
say, respectively. Under these conditions, the S/B ratios were 
similar in both the IP-One assay and intracellular calcium 
assay for measurement of antagonist activities. The IC50 
value of atropine was 2.93 nM determined from the intracel-
lular calcium assay which is similar to 1.82 nM obtained 
from the IP-One assay (Fig. 5b). For pirenzepine, the IC50 
values were 63.3 and 20.8 nM, respectively in intracellular 
calcium assay and IP-One assay (Fig. 5b). This result indi-
cates that the potencies of antagonists are similar and compa-
rable in both assays using EC80 amount of agonist.  
LOPAC Library Screenings in the IP-One and Intracel-
lular Calcium Assays 
  A DMSO plate was first tested to evaluate both assays in 
the antagonist screening mode with the EC80 concentration 
of carbachol. The IP-One assay in 1536-well plates was per-
formed in a homogenous assay format (Table 2). The S/B 
ratio was 1.86 fold and Z’ factor was 0.78 (Fig. 6a), indicat-
ing a robust screening assay. The no-wash calcium dye was 
used in the intracellular calcium assay with a newly available 
Table 1.  EC50 Values of four Gq-Coupled GPCRs Determined in the IP-One and Intracellular Calcium Assays 
GPCR Agonist  EC50(nM) (calcium assay) (a)  EC50(nM) (IP-One assay) (b)  Ratio b/a 
M1R Carbachol  16.1  535  33.2 
V1bR Vasopressin  0.032  1.10  34.4 
FFAR1 GW9508  5700  6300  1.1 
NPSR NPS  0.22  0.41  1.9 
Table 2.  IP-One Assay Protocol in 1536-Well Plate Format 
Step Parameter  Value  Description 
1 Cells  4  L 2000  cells/well 
2  Incubation  24 hrs  37°C, 5% CO2 
3  Compound   23 nl  in DMSO dilution 
4  Incubation  10 min  37°C, 5% CO2 
4 Reagent  1  l Carbachol  (EC80)  
5  Incubation  30 min  37°C, 5% CO2 
7 Reagents  1  l each  IP1-d2 and Eu-anti-IP1-Ab in cell lysis buffer, dispensing separately 
8  Incubation  30 min  Room temperature 
9  Detection  HTRF mode  ViewLux plate reader 76    Current Chemical Genomics, 2008, Volume 1  Liu et al. 
kinetic plate reader specifically designed for 1536-well plate 
assays (Table 3). The S/B ratio and Z’ determined from the 
intracellular calcium assay were 1.80 fold and 0.64, respec-
tively (Fig. 6b). Although the S/B ratios in both assays were 
smaller than these in the agonist assay mode, the Z’ factors 
were above 0.5 indicating that both assay were robust for 
compound screening.  
  The results of both the IP-One assay and intracellular 
calcium assays are calculated ratiometrically which compen-
sates for the relatively small S/B ratios for the assay per-
formance. Both IP-One and intracellular calcium assays de-
scribed here do not require cell wash nor medium aspiration 
and are thus suitable for high throughput screening. While 
the intracellular calcium assay requires a costly kinetic fluo-
rescence plate reader, the IP-One assay can be carried out 
using a standard fluorescence plate reader that is obviously a 
convenient and cost-effective alternative for compound 
screening with Gq-coupled GPCRs.  
  We then screened the LOPAC library in a quantitative 
high throughput screening (qHTS) format with both the IP-
One and the intracellular calcium assays. Since all com-
pounds were titrated in 15-concentrations, the active com-
pounds were evaluated by their potencies and the curve 
classes as it was discussed in detail previously [15]. The re-
sults of cholinergic antagonists were particularly examined 
in details and their potencies in two assays are compared in 
Table 4.  
Correlation of Antagonist Activities Between IP-One and 
Intracellular Calcium Assays 
  The LOPAC collection contains 30 known cholinergic 
antagonists including M1 specific, other subtype specific and 
 
 
 
 
 
 
 
 
 
 
Fig. (6). DMSO plate tests in a M1-CHO cell line for the intracellular calcium and IP-One assays. (a) Scatter plot of the results from IP-One 
assay. All wells were stimulated the EC80 amount of carbachol (4 μM). Column 2 was received 50 μM atropine (IC100). (b) Scatter plot of the 
results from intracellular calcium assay. All wells in this plate were stimulated with 0.1 μM carbachol (in EC80). Column 1 was treated with 
50 μM atropine (IC100) and column 2 was added with the EC100 amount of carbachol. 
 
Table 3.  Calcium Assay Protocol in 1536-Well Plate Format 
Step Parameter  Value  Description 
1 Cells  3  l 2000  cells/well 
2  Incubation  16-20 hrs  37°C, 5% CO2 
3 Reagent  3  l  No-wash calcium dye 
4  Incubation  60 min  37°C, 5% CO2 
5  Compound   23 nl  in DMSO dilution 
6  Incubation  10 min  Room temperature 
7  Detection  Basal signal  10 reads at 1 Hz 
8 Reagent  2  l Carbachol  (EC80) 
9  Detection  Antagonist response  4-minute reading at 1Hz 
 
 
 
 
 
 
 
Fig. (7). Correlation of known cholinergic antagonist activities 
between the IP-One and intracellular calcium assays. The LOPAC 
collection was screened in the qHTS format with both the IP-One 
assay and the calcium assay. The IC50 values of 30 know choliner-
gic antagonists determined from both screens were correlated. Comparison on Functional Assays for Gq-Coupled GPCRs  Current Chemical Genomics, 2008, Volume 1    77 
nonselective antagonists. The IC50 values of these 30 known 
antagonists determined from the IP-One assay correlated 
with these measured from the intracellular calcium assay 
(Fig.  7). Together with the results of atropine and piren-
zepine, it further demonstrated that the antagonist activities 
determined in this IP-One assay were similar to those ob-
tained from the intracellular calcium assay in the kinetic as-
say mode.  
  Taken together, the intracellular calcium assay measures 
the real-time kinetic changes of free Ca
2+ in live cells. It is a 
reliable assay method for screening compounds acting on 
Gq-coupled GPCRs; however, this method requires a special 
kinetic plate reader with the liquid handling capability for 
the addition of agonist to all the wells in an assay plate si-
multaneously. The tips on the multiple channel pipette head 
must be washed extensively before being used for the next 
assay plate. This tip washing step significantly limits the 
screening throughput and assay plate density in the previous 
version of instruments including FDSS-6000 and FLIPR 
Tetra. We have applied a newly designed FDSS-7000 plate 
reader which has one 1536-well pipetting head and three 
wash stations with sonicators. It can effectively and quickly 
wash tips for reuse and make the intracellular calcium assays 
Table 4.  IC50 Values (μM) of 30 Known Cholinergic Antagonists Determined in the IP-One and Intracellular Calcium Assays in 
M1-CHO Cells 
Compound   Property  Calcium Assay  IP-One Assay 
Tropicamide MAR  anta.  (M4)  2.00  3.16 
Atropine methyl bromide  MAR anta.  0.01  0.003 
Atropine sulfate  MAR anta.  0.01  0.001 
Atropine methyl nitrate  MAR anta.   0.013  0.001 
BW 284c51  Ach. Inh.  6.31  12.6 
Aminobenztropine MAR  anta.  0.016  0.003 
Benztropine mesylate  MAR anta.  0.008  0.013 
4-DAMP methiodide  M3 and M5 MAR anta.  0.016  0.006 
Dicyclomine hydrochloride  MAR anta.  0.039  0.631 
4-DAMP mustard hydrochloride  Irreversible MAR anta.  0.10  0.126 
L-Hyoscyamine MAR  anta.  0.01  0.501 
Ipratropium bromide  MAR anta.  0.016  0.004 
DL-Homatropine hydrobromide  MAR anta.  0.16  0.001 
Hexahydro-sila-difenidol hydro-
chloride, p-fluoro analog  MAR anta.  0.16  1.58 
MG 624  NAR anta.  0.13  0.398 
Methoctramine tetrahydrochloride  MAR anta.(M2 selective)  1.00  3.98 
Orphenadrine hydrochloride  MAR anta.  0.50  1.00 
Pancuronium bromide  skeletal muscle relaxant  10.0  12.6 
Oxybutynin Chloride  MAR anta.  0.025  0.039 
Pirenzepine dihydrochloride  MAR anta.  0.10  0.126 
Propantheline bromide  MAR anta.  0.012  0.001 
(-)-Scopolamine hydrobromide  MAR anta.  0.012  0.004 
(-)-Scopolamine methyl nitrate  MAR anta.  0.012  0.001 
(-)-Scopolamine,n-Butyl-, bromide  MAR anta.  0.16  0.50 
(-)-Scopolamine methyl bromide  MAR anta.  0.013  0.001 
Trihexyphenidyl hydrochloride  MAR anta.  0.025  0.0251 
N,N,N-trimethyl-1-(4-trans-
stilbenoxy)-2-propylammonium   NAR anta.  3.98  7.94 
Telenzepine dihydrochloride  MAR anta. (M1 select)  0.032  0.025 
WB 64  MAR anta.  0.398  0.398 
9-Amino-1,2,3,4-tetrahydroacridine   Ach inh.  15.8  10.0 
Note: MAR - muscarinic acetylcholine receptor; anta. – antagonist; Ach. Inh. – acetylcholinesterase inhibitor; NAR - Nicotinic acetylcholine receptor. 78    Current Chemical Genomics, 2008, Volume 1  Liu et al. 
robust in a 1536-well plate format; although the instrument 
is still costly. 
  Alternatively, the IP-One assay can be carried out with a 
standard plate reader without the requirement of a kinetic 
measurement. The HTRF assay format of the IP-One assay 
also reduces the well-to-well variation because the result is 
calculated in a ratiometric manner which can minimize the 
variations caused by cell number and dispensing errors 
among wells. The IP-One assay is also a homogenous assay 
format and has been miniaturized to 1536-well plates. The 
EC50 values of the agonists determined in the IP-One assay 
were similar to these reported in the radioactive IP assay. 
Thus, it is a useful alternative method for compound screen-
ing with Gq-protein coupled GPCRs. Compared with the 
intracellular calcium assay, the EC50 values of agonists in the 
IP-One assay could be less potent but the antagonist poten-
cies are similar in both assays. 
  In summary, we have optimized and miniaturized an IP-
One assay for the M1R, V1bR, FFAR1, and NPSR cell lines. 
The potencies of agonists determined from this IP-One assay 
are similar to these obtained from the traditional radioactive 
IP3 assay. The EC50 values of agonists determined from 
some GPCRs (FFAR1 and NPSR) were similar in both intra-
cellular calcium and IP-One assays, while these determined 
from others (M1R and V1bR) were less potent in the IP-One 
assay, probably due to the receptor reserve. In comparison 
with the intracellular calcium assay using the kinetic detec-
tion mode, the potencies of antagonist responses are similar 
in both assays. The IP-One assay is homogenous and robust 
without requirement of a costly kinetic plate reader. These 
results indicate that the TR-FRET based IP-One assay is an 
alternative method to screen large sizes of compound collec-
tions for the Gq-coupled GPCRs.  
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